002693 On Other Exchanges
Symbol
Exchange
Shenzhen

hainan shuangcheng pharmac-a (002693) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HAINAN SHUANGCHENG PHARMAC-A (002693)
\

Related News

No related news articles were found.

hainan shuangcheng pharmac-a (002693) Related Businessweek News

No Related Businessweek News Found

hainan shuangcheng pharmac-a (002693) Details

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, levocarnitine, clindamycin hydrochloride, thymopentin, famotidine, and thymalfasin for injections. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.

483 Employees
Last Reported Date: 04/18/19
Founded in 2000

hainan shuangcheng pharmac-a (002693) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hainan shuangcheng pharmac-a
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Approves Amendments to Articles of Association

Hainan Shuangcheng Pharmaceuticals Co., Ltd. approved amendments to the company's articles of association at the Annual General Meeting held on 15 May 2019.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019

Hainan Shuangcheng Pharmaceuticals Co., Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was CNY 78.836 million compared to CNY 95.765 million a year ago. Operating loss was CNY 11.658 million compared to CNY 6.864 million a year ago. Net loss was CNY 8.882 million compared to CNY 3.444 million a year ago. Basic loss per share from continuing operations was CNY 0.02 compared to CNY 0.01 a year ago.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q1, 2019 Results on Apr 30, 2019

Hainan Shuangcheng Pharmaceuticals Co., Ltd. announced that they will report Q1, 2019 results on Apr 30, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies
 

Industry Analysis

002693

Industry Average

Valuation 002693 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit www.shuangchengmed.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.